---
title: "BDC Capital's $150M Life Sciences Fund: Canada's Medtech Layer Gets Capital"
description: "BDC Capital's life sciences venture fund bolsters Canadian therapeutics and medtech — an underrated pipeline for U.S. and EU follow-on rounds."
date: 2026-04-09T00:00:00.000Z
tags: ["2026-vc-news", "venture-capital", "fund-news", "healthcare", "biotech"]
source: https://venturecapitaltracker.com/2026-bdc-capital-life-sciences-150m-fund
---

# BDC Capital's $150M Life Sciences Fund: Canada's Medtech Layer Gets Capital

> BDC Capital's life sciences venture fund bolsters Canadian therapeutics and medtech — an underrated pipeline for U.S. and EU follow-on rounds.

**BDC Capital Life Sciences Venture Fund** announced a **$150M** vehicle on April 9, 2026, focused on therapeutics and medical technologies.

### The problem this fund is attacking
Canadian life sciences startups have strong science (Toronto–Montreal–Vancouver corridor) but historically rely on U.S. investors for Series B and beyond. A domestic $150M fund reduces friction and keeps companies scaling locally.

### Why this is a live problem now
- AI-driven drug discovery is lowering pre-clinical cost curves.
- Canadian research institutions have robust translational pipelines.
- U.S. capital availability for Canadian HQs has tightened since 2023.

### Competitive map
- **Lumira Ventures**, **CTI Life Sciences**, **Amplitude Ventures**, **Versant** (cross-border).
- U.S. firms with Canadian practice: **OrbiMed**, **RA Capital**, **Arch Venture**.

### Market signal (the number to remember)
- **$150M** for domestic life sciences venture is meaningful given typical Canadian life-sciences fund sizes.

### Practical takeaway (operator + investor)
1. **Biotech founders**: Canadian capital plus U.S. clinical partners can be a reasonable path to approval.
2. **Investors**: Watch for oncology, rare disease, and AI-drug-design seed-A companies seeded by BDC.

### Sources
1. Yutori Scouts fund tracker: https://scouts.yutori.com/8b847103-9d57-41bd-b907-94108a38ecfe

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.